KVISTGAARD, Denmark, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Copenhagen:BAVA) announced today that BARDA (Biomedical Advanced Research and Development Authority) has exercised the next option under the contract for the development of a freeze-dried version of Bavarian Nordic's IMVAMUNE(R) smallpox vaccine.
The option, which was triggered by the successful completion of certain development milestones, provides next year's funding under the contract,totalling approx. USD14 million. The total prospective value of the five-year contract, awarded in 2009, is USD40 million.
The contract provides funds to validate the new freeze-dried manufacturing process and the associated pre-clinical and clinical studies to support the advanced development of a freeze-dried version of IMVAMUNE(R). The freeze-dried development activities are performed in parallel to the licensure activities of the current liquid-frozen IMVAMUNE(R) formulation under the RFP-3 contract.
The above does not affect the company's expectations for the 2010 full year results.
Bavarian Nordic's President & CEO Anders Hedegaard commented: "We are pleased with the US Government's continued support to advance the development of IMVAMUNE(R) as a safer smallpox vaccine. Besides our ongoing contract for the development and delivery of 20 million doses of IMVAMUNE(R) with an option of additional 60 million doses in the current liquid-frozen formulation to the US Strategic National Stockpile, we are committed to the development of a freeze-dried version of IMVAMUNE(R), which offers a number of new advantages, thus representing an additional business opportunity which we intend to explore."
CONTACT: Bavarian Nordic A/S Anders Hedegaard, President & CEO +45 23 20 30 64
